These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 18379355

  • 1. Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group.
    Agarwala A, Fisher W, Bruetman D, McClean J, Taber D, Titzer M, Juliar B, Yu M, Breen T, Einhorn LH, Hanna N.
    J Thorac Oncol; 2008 Apr; 3(4):374-9. PubMed ID: 18379355
    [Abstract] [Full Text] [Related]

  • 2. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
    Gadgeel SM, Ruckdeschel JC, Heath EI, Heilbrun LK, Venkatramanamoorthy R, Wozniak A.
    J Thorac Oncol; 2007 Apr; 2(4):299-305. PubMed ID: 17409801
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
    Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Lee DH, Liu Y, Yoh K, Zhou JY, Shi X, Webster A, Jiang H, Mok TS.
    Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. First-line gefitinib treatment for patients with advanced non-small cell lung cancer with poor performance status.
    Lee YJ, Kim HT, Han JY, Yun T, Lee GK, Kim HY, Sung JH, Lee JS.
    J Thorac Oncol; 2010 Mar; 5(3):361-8. PubMed ID: 20107420
    [Abstract] [Full Text] [Related]

  • 8. Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.
    Ichihara E, Hotta K, Nogami N, Kuyama S, Kishino D, Fujii M, Kozuki T, Tabata M, Harada D, Chikamori K, Aoe K, Ueoka H, Hosokawa S, Bessho A, Hisamoto-Sato A, Kubo T, Oze I, Takigawa N, Tanimoto M, Kiura K.
    J Thorac Oncol; 2015 Mar; 10(3):486-91. PubMed ID: 25695221
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
    Argiris A, Mittal N.
    Lung Cancer; 2004 Mar; 43(3):317-22. PubMed ID: 15165090
    [Abstract] [Full Text] [Related]

  • 12. Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status.
    Minami S, Kijima T, Hamaguchi M, Nakatani T, Koba T, Takahashi R, Takeuchi Y, Kida H, Nagatomo I, Yamamoto S, Tachibana I, Komuta K, Kawase I.
    Lung Cancer; 2013 Nov; 82(2):271-5. PubMed ID: 23993733
    [Abstract] [Full Text] [Related]

  • 13. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
    Sunaga N, Tomizawa Y, Yanagitani N, Iijima H, Kaira K, Shimizu K, Tanaka S, Suga T, Hisada T, Ishizuka T, Saito R, Dobashi K, Mori M.
    Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623
    [Abstract] [Full Text] [Related]

  • 14. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
    Hattori Y, Satouchi M, Shimada T, Urata Y, Yoneda T, Mori M, Nishimura T, Sunadome H, Kumagai T, Imamura F, Fujita S, Kaji R, Hata A, Tachihara M, Morita S, Negoro S.
    Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650
    [Abstract] [Full Text] [Related]

  • 15. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.
    Fidler MJ, Argiris A, Patel JD, Johnson DH, Sandler A, Villaflor VM, Coon J, Buckingham L, Kaiser K, Basu S, Bonomi P.
    Clin Cancer Res; 2008 Apr 01; 14(7):2088-94. PubMed ID: 18381949
    [Abstract] [Full Text] [Related]

  • 16. Prospective assessment of pemetrexed or pemetrexed plus platinum in combination with gefitinib or erlotinib in patients with acquired resistance to gefitinib or erlotinib: a phase II exploratory and preliminary study.
    Yu S, Zhang B, Xiang C, Shu Y, Wu H, Huang X, Yu Q, Yin Y, Guo R.
    Clin Lung Cancer; 2015 Mar 01; 16(2):121-7. PubMed ID: 25450874
    [Abstract] [Full Text] [Related]

  • 17. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
    Kwon JH, Kim JH, Lee JA, Shin HC, Kim HJ, Song HH, Jung JY, Kim HY, Choi DR, Kim HS, Park YI, Zang DY.
    Cancer Chemother Pharmacol; 2010 Oct 01; 66(5):889-97. PubMed ID: 20091311
    [Abstract] [Full Text] [Related]

  • 18. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
    Spigel DR, Burris HA, Greco FA, Shipley DL, Friedman EK, Waterhouse DM, Whorf RC, Mitchell RB, Daniel DB, Zangmeister J, Bass JD, Hainsworth JD.
    J Clin Oncol; 2011 Jun 20; 29(18):2582-9. PubMed ID: 21576636
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung cancer.
    Gadgeel SM, Wozniak A, Ruckdeschel JC, Heilbrun LK, Venkatramanamoorthy R, Chaplen RA, Kraut MJ, Kalemkerian GP.
    J Thorac Oncol; 2008 Nov 20; 3(11):1293-300. PubMed ID: 18978565
    [Abstract] [Full Text] [Related]

  • 20. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH, Lee JY, Sun JM, Ahn JS, Park K, Ahn MJ.
    J Thorac Oncol; 2014 Apr 20; 9(4):506-11. PubMed ID: 24736073
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.